New US approval for Takeda’s Alunbrig

26th May 2020 Uncategorised 0

The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC

More: New US approval for Takeda’s Alunbrig
Source: News